Skip to main content

Advertisement

Table 1 Maximal specific activities of DTPA- and DOTA-conjugated compounds

From: Improved labelling of DTPA- and DOTA-conjugated peptides and antibodies with 111In in HEPES and MES buffer

Compound NaAc (MBq/nmol)a NH4Ac (MBq/nmol)a MES (MBq/nmol)a HEPES (MBq/nmol)a Maximum theoretical SAb (GBq/nmol)
DTPA-exendin-3 379 ± 16 207 ± 20 717 ± 29 837 ± 6 1.7
DTPA-octreotide 95 ± 5 52 ± 4 248 ± 24 650 ± 10 1.7
DTPA-cG250 338 ± 60 246 ± 37 835 ± 46 939 ± 50 5.2
DOTA-exendin-3 23 ± 8 22 ± 1 56 ± 4 38 ± 16 1.7
DOTA-octreotide 38 ± 0 39 ± 0 39 ± 0 39 ± 0 1.7
DOTA-cG250 330 ± 87 254 ± 2 947 ± 44 1018 ± 7 12.4
  1. aMaximal specific activities (in megabecquerel per nanomole) and the bmaximum theoretical SA (in gigabecquerel per nanomole) for DTPA-exendin-3, DOTA-exendin-3, DTPA-octreotide, DOTA-octreotide, DTPA-anti-CAIX and DOTA-anti-CAIX in 0.1-M NaAc, NH4Ac, MES and HEPES buffers. The maximum theoretical SA is calculated, assuming that 1 nmol DTPA or DOTA can complex 1 nmol 111In.